NCT01490112View on ClinicalTrials.gov

Surveillance Study of NovoRapid® for New Drug Re-examination

CompletedOBSERVATIONAL
Enrollment

1,239

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

insulin aspart

Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks

Trial Locations (1)

137-920

Novo Nordisk Investigational Site, Seoul

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY